A detailed history of Qube Research & Technologies LTD transactions in Cerus Corp stock. As of the latest transaction made, Qube Research & Technologies LTD holds 253,646 shares of CERS stock, worth $400,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
253,646
Previous 92,133 175.3%
Holding current value
$400,760
Previous $162,000 172.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.7 - $2.39 $274,572 - $386,016
161,513 Added 175.3%
253,646 $441,000
Q2 2024

Aug 14, 2024

BUY
$1.62 - $2.04 $149,255 - $187,951
92,133 New
92,133 $162,000
Q1 2023

May 15, 2023

SELL
$2.65 - $3.81 $566,766 - $814,859
-213,874 Reduced 82.82%
44,354 $131,000
Q4 2022

Feb 14, 2023

BUY
$3.38 - $4.22 $449,644 - $561,390
133,031 Added 106.26%
258,228 $942,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $429,425 - $729,898
125,197 New
125,197 $451,000
Q2 2022

Aug 15, 2022

SELL
$4.41 - $5.69 $405,168 - $522,768
-91,875 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$4.81 - $6.99 $441,918 - $642,206
91,875 New
91,875 $504,000
Q3 2021

Nov 12, 2021

SELL
$4.79 - $6.68 $219,894 - $306,658
-45,907 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$5.35 - $6.35 $245,602 - $291,509
45,907 New
45,907 $271,000
Q1 2021

May 14, 2021

SELL
$5.68 - $7.87 $251,868 - $348,979
-44,343 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$5.25 - $8.56 $167,868 - $273,706
31,975 Added 258.53%
44,343 $307,000
Q3 2020

Nov 12, 2020

BUY
$5.78 - $7.47 $173 - $224
30 Added 0.24%
12,368 $77,000
Q2 2020

Aug 14, 2020

BUY
$4.5 - $7.02 $55,521 - $86,612
12,338 New
12,338 $81,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $280M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.